Literature DB >> 27738905

Tanapoxvirus lacking a neuregulin-like gene regresses human melanoma tumors in nude mice.

Tiantian Zhang1, Yogesh R Suryawanshi1, Dennis H Kordish1, Helene M Woyczesczyk1, David Jeng1, Karim Essani2.   

Abstract

Neuregulin (NRG), an epidermal growth factor is known to promote the growth of various cell types, including human melanoma cells through ErbB family of tyrosine kinases receptors. Tanapoxvirus (TPV)-encoded protein TPV-15L, a functional mimic of NRG, also acts through ErbB receptors. Here, we show that the TPV-15L protein promotes melanoma proliferation. TPV recombinant generated by deleting the 15L gene (TPVΔ15L) showed replication ability similar to that of wild-type TPV (wtTPV) in owl monkey kidney cells, human lung fibroblast (WI-38) cells, and human melanoma (SK-MEL-3) cells. However, a TPV recombinant with both 15L and the thymidine kinase (TK) gene 66R ablated (TPVΔ15LΔ66R) replicated less efficiently compared to TPVΔ15L and the parental virus. TPVΔ15L exhibited more robust tumor regression in the melanoma-bearing nude mice compared to other TPV recombinants. Our results indicate that deletion of TPV-15L gene product which facilitates the growth of human melanoma cells can be an effective strategy to enhance the oncolytic potential of TPV for the treatment of melanoma.

Entities:  

Keywords:  Melanoma; Neuregulin; Oncolytic virus; Tanapoxvirus; Thymidine kinase

Mesh:

Substances:

Year:  2016        PMID: 27738905      PMCID: PMC5300959          DOI: 10.1007/s11262-016-1402-2

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  72 in total

1.  Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer.

Authors:  Lili Zhao; Jinfa Gu; Aiwen Dong; Yanhong Zhang; Liu Zhong; Lingfeng He; Yigang Wang; Jinhe Zhang; Zilai Zhang; Jin Huiwang; Qijun Qian; Cheng Qian; Xinyuan Liu
Journal:  Hum Gene Ther       Date:  2005-07       Impact factor: 5.695

Review 2.  Talimogene laherparepvec in the treatment of melanoma.

Authors:  Elizabeth S Appleton; Samantha Turnbull; Christy Ralph; Emma West; Karen Scott; Kevin Harrington; Hardev Pandha; Alan Melcher
Journal:  Expert Opin Biol Ther       Date:  2015       Impact factor: 4.388

Review 3.  Replication-selective oncolytic viruses in the treatment of cancer.

Authors:  Bart Everts; Henk G van der Poel
Journal:  Cancer Gene Ther       Date:  2005-02       Impact factor: 5.987

4.  Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors.

Authors:  K R Irvine; R S Chamberlain; E P Shulman; D R Surman; S A Rosenberg; N P Restifo
Journal:  J Natl Cancer Inst       Date:  1997-11-05       Impact factor: 13.506

5.  NRG1 / ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation.

Authors:  Kristina Buac; Mai Xu; Julie Cronin; Ashani T Weeraratna; Stephen M Hewitt; William J Pavan
Journal:  Pigment Cell Melanoma Res       Date:  2009-07-30       Impact factor: 4.693

6.  Transforming growth factor alpha, Shope fibroma growth factor, and vaccinia growth factor can replace myxoma growth factor in the induction of myxomatosis in rabbits.

Authors:  A Opgenorth; N Nation; K Graham; G McFadden
Journal:  Virology       Date:  1993-02       Impact factor: 3.616

7.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

8.  Survival rates of patients with metastatic malignant melanoma.

Authors:  A Sandru; S Voinea; E Panaitescu; A Blidaru
Journal:  J Med Life       Date:  2014 Oct-Dec

9.  ERBB3 is required for metastasis formation of melanoma cells.

Authors:  S Tiwary; M Preziosi; P G Rothberg; N Zeitouni; N Corson; L Xu
Journal:  Oncogenesis       Date:  2014-07-07       Impact factor: 7.485

Review 10.  Going viral: a review of replication-selective oncolytic adenoviruses.

Authors:  Christopher Larson; Bryan Oronsky; Jan Scicinski; Gary R Fanger; Meaghan Stirn; Arnold Oronsky; Tony R Reid
Journal:  Oncotarget       Date:  2015-08-21
View more
  5 in total

Review 1.  Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

Authors:  Jonathan G Pol; Sarah Lévesque; Samuel T Workenhe; Shashi Gujar; Fabrice Le Boeuf; Derek R Clements; Jean-Eudes Fahrner; Laetitia Fend; John C Bell; Karen L Mossman; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-08-27       Impact factor: 8.110

Review 2.  Oncolytic viruses: emerging options for the treatment of breast cancer.

Authors:  Yogesh R Suryawanshi; Tiantian Zhang; Karim Essani
Journal:  Med Oncol       Date:  2017-02-09       Impact factor: 3.738

3.  Tanapoxvirus lacking the 15L gene inhibits melanoma cell growth in vitro by inducing interferon-λ1 release.

Authors:  Tiantian Zhang; Karim Essani
Journal:  Virus Genes       Date:  2017-02-10       Impact factor: 2.198

4.  T-independent response mediated by oncolytic tanapoxvirus recombinants expressing interleukin-2 and monocyte chemoattractant protein-1 suppresses human triple negative breast tumors.

Authors:  Yogesh R Suryawanashi; Tiantian Zhang; Helene M Woyczesczyk; John Christie; Emily Byers; Steven Kohler; Robert Eversole; Charles Mackenzie; Karim Essani
Journal:  Med Oncol       Date:  2017-05-02       Impact factor: 3.738

5.  Neutralization of matrix metalloproteinase-9 potentially enhances oncolytic efficacy of tanapox virus for melanoma therapy.

Authors:  Tiantian Zhang; Yogesh R Suryawanshi; Blair R Szymczyna; Karim Essani
Journal:  Med Oncol       Date:  2017-06-07       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.